32 research outputs found
The Solenoidal Large Intensity Device (SoLID) for JLab 12 GeV
The Solenoidal Large Intensity Device (SoLID) is a new experimental apparatus
planned for Hall A at the Thomas Jefferson National Accelerator Facility
(JLab). SoLID will combine large angular and momentum acceptance with the
capability to handle very high data rates at high luminosity. With a slate of
approved high-impact physics experiments, SoLID will push JLab to a new limit
at the QCD intensity frontier that will exploit the full potential of its 12
GeV electron beam. In this paper, we present an overview of the rich physics
program that can be realized with SoLID, which encompasses the tomography of
the nucleon in 3-D momentum space from Semi-Inclusive Deep Inelastic Scattering
(SIDIS), expanding the phase space in the search for new physics and novel
hadronic effects in parity-violating DIS (PVDIS), a precision measurement of
production at threshold that probes the gluon field and its
contribution to the proton mass, tomography of the nucleon in combined
coordinate and momentum space with deep exclusive reactions, and more. To meet
the challenging requirements, the design of SoLID described here takes full
advantage of recent progress in detector, data acquisition and computing
technologies. In addition, we outline potential experiments beyond the
currently approved program and discuss the physics that could be explored
should upgrades of CEBAF become a reality in the future.Comment: This white paper for the SoLID program at Jefferson Lab was prepared
in part as an input to the 2023 NSAC Long Range Planning exercise. To be
submitted to J. Phys.
Strong Interaction Physics at the Luminosity Frontier with 22 GeV Electrons at Jefferson Lab
This document presents the initial scientific case for upgrading the
Continuous Electron Beam Accelerator Facility (CEBAF) at Jefferson Lab (JLab)
to 22 GeV. It is the result of a community effort, incorporating insights from
a series of workshops conducted between March 2022 and April 2023. With a track
record of over 25 years in delivering the world's most intense and precise
multi-GeV electron beams, CEBAF's potential for a higher energy upgrade
presents a unique opportunity for an innovative nuclear physics program, which
seamlessly integrates a rich historical background with a promising future. The
proposed physics program encompass a diverse range of investigations centered
around the nonperturbative dynamics inherent in hadron structure and the
exploration of strongly interacting systems. It builds upon the exceptional
capabilities of CEBAF in high-luminosity operations, the availability of
existing or planned Hall equipment, and recent advancements in accelerator
technology. The proposed program cover various scientific topics, including
Hadron Spectroscopy, Partonic Structure and Spin, Hadronization and Transverse
Momentum, Spatial Structure, Mechanical Properties, Form Factors and Emergent
Hadron Mass, Hadron-Quark Transition, and Nuclear Dynamics at Extreme
Conditions, as well as QCD Confinement and Fundamental Symmetries. Each topic
highlights the key measurements achievable at a 22 GeV CEBAF accelerator.
Furthermore, this document outlines the significant physics outcomes and unique
aspects of these programs that distinguish them from other existing or planned
facilities. In summary, this document provides an exciting rationale for the
energy upgrade of CEBAF to 22 GeV, outlining the transformative scientific
potential that lies within reach, and the remarkable opportunities it offers
for advancing our understanding of hadron physics and related fundamental
phenomena.Comment: Updates to the list of authors; Preprint number changed from theory
to experiment; Updates to sections 4 and 6, including additional figure
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes
Recommended from our members
[Spin dependent phenomena in medium energy physics]. [Syracuse Univ. , Syracuse, New York]
The Syracuse University Medium Energy Physics Group was actively engaged in several research projects. A laser was used to polarize muonic atoms with the goal of measuring fundamental spin-dependent parameters in the reaction [mu][sup [minus]] + [sup 3]He [yields] [sup 3]H + [nu]. Time-averaged polarizations of 26.8[plus minus]2.3% were achieved for the muon in muonic [sup 3]He. The new approach uses atomic spin-dependent reactions between laser polarized Rb vapor and muonic helium. To exploit these high polarizations in a muon capture experiment an ion chamber which will detect the recoil tritons and also serve as a polarizing cell. Final data-taking will begin for an experiment to measure the spin-dependent structure functions of the neutron. A 288-element hodoscope system which features good timing and precise mechanical tolerances was constructed and evaluated
A Model for Allocating Resources to Research Programs by Evaluating Technical Importance and Research Productivity
Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques.
Mother-to-infant transmission (MTIT) of HIV is a serious global health concern, with over 300,000 children newly infected in 2011. SIV infection of rhesus macaques (RMs) results in similar rates of MTIT to that of HIV in humans. In contrast, SIV infection of sooty mangabeys (SMs) rarely results in MTIT. The mechanisms underlying protection from MTIT in SMs are unknown. In this study we tested the hypotheses that breast milk factors and/or target cell availability dictate the rate of MTIT in RMs (transmitters) and SMs (non-transmitters). We measured viral loads (cell-free and cell-associated), levels of immune mediators, and the ability to inhibit SIV infection in vitro in milk obtained from lactating RMs and SMs. In addition, we assessed the levels of target cells (CD4+CCR5+ T cells) in gastrointestinal and lymphoid tissues, including those relevant to breastfeeding transmission, as well as peripheral blood from uninfected RM and SM infants. We found that frequently-transmitting RMs did not have higher levels of cell-free or cell-associated viral loads in milk compared to rarely-transmitting SMs. Milk from both RMs and SMs moderately inhibited in vitro SIV infection, and presence of the examined immune mediators in these two species did not readily explain the differential rates of transmission. Importantly, we found that the percentage of CD4+CCR5+ T cells was significantly lower in all tissues in infant SMs as compared to infant RMs despite robust levels of CD4+ T cell proliferation in both species. The difference between the frequently-transmitting RMs and rarely-transmitting SMs was most pronounced in CD4+ memory T cells in the spleen, jejunum, and colon as well as in central and effector memory CD4+ T cells in the peripheral blood. We propose that limited availability of SIV target cells in infant SMs represents a key evolutionary adaptation to reduce the risk of MTIT in SIV-infected SMs